Mainstream

Abivax skyrockets 400% as late-stage trial for lead asset succeeds in ulcerative colitis

Abivax skyrockets 400% as late-stage trial for lead asset succeeds in ulcerative colitis

Post ContentabvxRead More

You might also be interested in reading Dormant Bitcoin Giant Stirs, Moves 1,000 BTC After Decade in Hiding.

July 23, 2025
In Mainstream